Chemotherapy and chemoimmunotherapy of metastatic malignant melanoma. Review of the literature and current data;Chimiotherapie et chimioimmunotherapie du melanome malin metastatique: Revue de litterature et donnees recentes

Oncologie

Volumn 1, Issue 1, 1999, Pages 18-25

  Coeffic, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; FOTEMUSTINE; INTERLEUKIN 2; LOMUSTINE; PACLITAXEL; SEMUSTINE; TAMOXIFEN; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; METASTASIS; REVIEW;

EID: 2442722134     PISSN: 09413804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Wingo P, Tong P, Bolden S. Cancer statistics. J Clin Oncol 1995; 45: 8-30
2. Balch MH, Houghton AN, Peters LJ. Cutaneous melanoma. In: De Vita VT, Heliman S, Rosenberg SA, Eds. Cancer: Principles and practise of oncology. Philadelphia, Pa. JB Lippincott 1993: 1612-1661
3. Hill GJ, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma stage IV. Late results after complete response to chemotherapy. Cancer 1984; 53: 1299-1305
4. Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydratation with and without mannitol diuresic in refractory disseminated malignant melanoma: A South-West Oncology Group Study. Cancer Treat Rep 1982; 66: 31-33
5. Schilcher RB, Wessens M, Niderle M, Seeber S, Schmidt CG. Phase II evaluation of fractionated of low and single high-dose cisplatin in various tumors. J Cancer Res Clin Oncol 1984; 107:57-60
6. Song SY, Chary KK, Higby DJ, Henderson ES, Klein E. Cisdiamminedichloride platinum (II) in the treatment of metastatic malignant melanoma. Clin Res 1977; 25: 411
7. Jacquillat C, Khayat D, Banzet P, et al. Final report on a french Multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873-78
8. Khayat D, Avril MF, Auclerc G, Weil M, Gérard B, Bizzari JP. Clinical value of the nitrosourea fotemustine in disseminated malignat melanoma: overview on 1022 patients including 144 patients with cerebral metastases. Proc Am Soc Clin Oncol 1993; 12: 1343
9. Retsas S, Peat E, Ashford R, et al. Updated results of vindesine as a single agent in the therapy of advanced malignant melanoma. J Cancer Clin Oncol 1982; 18: 1293-95
10. Rowinsky EK, Mc Guire WP. Taxol: present status and future prospects. Contemp Oncol 1991; 29-36
11. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced maligant melanoma: A phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 8: 1061-64
12. Bedikian A, Legha S, Genkins J, et al. Phase II trial of docetaxel in patients (pts) with advanced melanoma previously untreated with chemotherapy. Proc Am Soc Clin Oncol 1995; 14: 1304
13. Del Prete SA, Maurer LH, O'Donnel J, et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 1403-1405
14. McClay EF, Mastrangelo MJ, Sprandio JD Bellet RE, and Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatement of metastatic melanoma. Cancer 1989; 63: 1292-95
15. Buzaid AC, Legha S, Winn R, et al. Cisplatin, vinblastine and dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial. Proc Am Soc Clin Oncol 1993; 12: 1328
16. Avril MF, Bonneterre J, Cupissol D, et al. Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992; 11: 1807-11
17. Khayat D, Borel C, Benhammouda A, et al. Active three drugs (fotemustine, dacarbazine and vindesine) outpatient combination in advanced malignant melanoma. Proc Am Soc Clin Oncol 1992; 33: 1336
18. Steffens T, Bajorin DF, Chapman PB, et al. A phase II trial of high-dose cisplatin and dacarbazin. Cancer 1991; 68: 1230-37
19. Buzaid AC, Legha S, Winn R, et al. Cisplatin, vinblastine and dacarbazine vs dacarbazine alone in metastatic melanoma: Preliminary results of a phase III Cancer Community Oncology Program trial. Proc Am Soc Clin Oncol 1993; 12: 389 (1328)
20. Ringborg U, Rudenstam CM, Hansson J, Hafstrom L, Stenstam B, Strander H. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 1989; 6: 285-9
21. Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164-8
22. Kirkwood JM. Studies of Interferons in the therapy of melanoma. Semin Oncol 1991; 18: 83-89
23. Legha S. Current therapy for Melanoma. Semin Oncol 1989; 16: 34-44.
24. Lindemann A, Brossart P, Hoffken K, et al. Immunomodulatory effects of ultra-dose interleukine 2 in ancer patients: A phase IB study. Cancer Immunol Immunother 1993; 37: 307-15
25. Rosenberg SA, Lotze MJ, Muul LM, et al. A progress report on the treatment of 157 patients with advanced ancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 16: 889-97
26. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 15: 898-905
27. Richards JM, Bajorin DF, Vogelzang N, et al. Treatment of metastatic melanoma with continuous intravenous IL2 +/- LAK cells: A randomized trial. Proc Am Soc Clin Oncol 1990; 9: 1080
28. Koretz MJ, Lawson DH, York RM, et al. Randomized study of interleukine 2 versus interleukine 2-LAK for treatment of melanoma and renal cell Cancer. Arch Surg 1991; 126: 898-903
29. McCabe MS, Stablein D, Hawkins MJ. The modified group C experience-Phase III randomized trials of interleukine 2 vs interleukine 2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 1991; 10: 714
30. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622-32
31. Brunda MJ, Bellantoni D, Sulich V. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987; 40: 365-71
32. Whitehead RP, Figlin R, Citron ML, et al. A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma. J Immunother 1993; 13: 117-21
33. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863-74
34. Sparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969-77
35. Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 1990; 171: 249-63
36. Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Semin Oncol 1989; 16: 230-53
37. Berd D, Maguire HC Jr, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44: 5439-43
38. Chabot GG, Flaherty LE, Valdivieso M, et al. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother Pharmacol 1990; 27: 157-60
39. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-8.
40. Thompson DB, Adena M, McLed GRC, et al. Interferon alpha does not improve response or survival when added to dacarbazine in metastatic melanoma: Results of a multiinstitutional Australian randomised trial QMP8704. Proc Am Soc Clin Oncol 1992; 11: 1177
41. Bajetta E, Di Leo A, Zampino MG, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806-11
42. Richner J, Joss RA, Goldhirsch A, Brunner KW. Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma. Eur J Cancer 1992; 28: 1044-7
43. Margolin KA, Doroshow JH, Akman SA, et al. Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma. J Clin Oncol 1992; 10: 1574-8
44. Mitchell MS, Kempf RA, Harel W, et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988; 6: 409-24
45. Mitchell MS. Principles of combining biomodulators with cytotoxic agents in vivo. Semin Oncol 1992; 19: 51-6
46. Papadopoulos NEJ, Howard JG, Murray JL, et al. Phase II DTIC and interleukine 2 Trial for metastatic malignant melanoma. Proc Am Soc Clin Oncol 1990; 277(1072)
47. Dillman RO, Oldham RK, Barth NM. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 1990; 82: 1345-1349
48. Demchak PA, Mier JW, Robert NJ, et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991; 9: 1821-30
49. Antoine EC, Benhammouda A, Bernard A, et al. Salpetriere Hospital experience with bio chemotherapy in metastatic melanoma. Cancer J Sci Am 1997; 3: S16-S21
50. Dorval T, Négrier S, Chevreau C, et al. Results of a french multicentric randomized trial of chemoimmunotherapy with or without interferon in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1994; 13: 1347
51. Richards JM, Mehta N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-43
52. Atzpodien J, Lopez Hanninen E, Kirchner H, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer. 1995; 31: 876-81
53. Blair S, Flaherty L, Valdiviaso M, et al. Comparison of high dose interleukine 2 with combined chemotherapy low-dose IL2 in metastatic malingnant melanoma. Proc Am Soc Clin Oncol 1991; 10: 1031
54. Hamblin TJ, Davies B, Sadullah S, et al. A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatine, interleukine 2 and interferon alpha. Proc Am Soc Clin Oncol 1991; 10: 1029
55. Flaherty LE, Robinson W, Redman BG, et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993; 71: 3520-25
56. Atkins MB, O'Boyle KR, Sosman JA, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969-77
57. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7: 827-35
58. Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993; 20: 27-32
59. Bernengo MG, Doveil GC, Bertero M, et al. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma. A pilot study Melanoma Res 1996; 6: 257-65
60. Dreno B, Cupissol B, Guillot B, et al. Subcutaneous interleukin-2 (IL2) and cisplatin and interferon alpha 2a (INF alpha 2a) for metastatic melanoma. Sixth International Congress on anti-cancer treatment 1996: 107
61. McClay EF, Mastrangelo MJ, Sprandio JD, et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63: 1292-5
62. Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:2083-90
63. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743-51
64. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and. Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15: 2579-88
65. Maral J. Long term follow up of patients with metastatic malignant melanoma treated with continuous infusion-IL2 alone or in combination. Eighth international congress on anti-cancer treatment 1998: 1560